The Cell Therapy stream explores the critical challenges facing the analysis, quality and manufacture of cell-based therapies. Topics include product and process characterization, CMC strategies, autologous and allogeneic manufacturing strategies, automation and supply for CAR Ts and next-generation cell therapies such as NK cells, TIL and TCR-based therapies. The stream is paired with the Gene Therapy CMC and Analytics track.

Conferences Include:

Keynote Speakers:

Don W. Fink, Jr., PhD, Master Practice Expert, Regulatory, Dark Horse Consulting

Mark Galbraith, PhD, Head, Quality Control and Analytical Sciences, Spark Therapeutics

Andrew W. Harmon, PhD, Biologist, CMC Reviewer, Division of Cellular and Gene Therapies, Office of Tissues and Advanced Therapies, FDA CDER